Baxter, M. A.Spender, L. C.Cairns, D.Walsh, S.Oparka, R.Porter, R. J.Bray, S.Skinner, G.King, S.Turbitt, J.Collinson, D.Miedzybrodzka, Z. H.Jellema, G.Logan, G.Kennedy, R. D.Turkington, R. C.McLean, M. H.Swinson, D.Grabsch, H. I.Lord, S.Seymour, M. J.Hall, P. S.Petty, R. D.2024-07-252024-07-252024-05Baxter, M A, Spender, L C, Cairns, D, Walsh, S, Oparka, R, Porter, R J, Bray, S, Skinner, G, King, S, Turbitt, J, Collinson, D, Miedzybrodzka, Z H, Jellema, G, Logan, G, Kennedy, R D, Turkington, R C, McLean, M H, Swinson, D, Grabsch, H I, Lord, S, Seymour, M J, Hall, P S & Petty, R D 2024, 'An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma', ESMO Open, vol. 9, no. 5, 103450. https://doi.org/10.1016/j.esmoop.2024.1034502059-7029ORCID: /0000-0002-7443-2653/work/164506351ORCID: /0000-0003-2890-8136/work/175113449https://hdl.handle.net/2164/23915121152752engSDG 3 - Good Health and Well-beingDNA damage immune responseepidermal growth factor receptorgastroesophageal adenocarcinomaimmune checkpoint inhibitorstumour microenvironmentRC0254 Neoplasms. Tumors. Oncology (including Cancer)OncologyCancer ResearchRC0254Journal article10.1016/j.esmoop.2024.103450https://www.scopus.com/pages/publications/85192856522